| Safety and regulation
A law-firm summary dated September 10, 2026 reports that the Fifth Circuit upheld the FDA decisions that the semaglutide and tirzepatide shortages were over. The summary says compounders can no longer rely on the shortage exception for large-scale copies, while patient-specific compounding can continue when legal requirements are met.
Worth knowing: The Atlas has not read the court decision itself, which is unpublished, so treat this as a secondary report.
Related: Compounded versus brand-name medicines | What a 503A pharmacy is
Source: Clark Hill law-firm news item, September 10, 2026. Secondary summary of an unpublished court decision; the Atlas has not read the decision Trade press, secondary source.